title: A phase II study of flutamide in ovarian cancer.
abstract: A phase II study of flutamide was conducted in 24 patients with stage III and IV ovarian cancer who failed chemotherapy and who had measurable disease. Flutamide was administered at a dose of 100 mg three times daily continuously until evidence of progression. Partial response observed in 1 of the 23 evaluable patients (4.3%) lasted 3 months. Two patients had stable disease (8.7%) for 7 and 8 months. The remaining 20 patients had progression of disease within 3 months. Toxicity was mild.
authors.affiliation: Second Medical Oncology Department, St. Savas Regional Oncology Hospital, Athens, Greece.
authors.forename: M
authors.initials: M
authors.lastname: Vassilomanolakis
authors.forename: G
authors.initials: G
authors.lastname: Koumakis
authors.forename: V
authors.initials: V
authors.lastname: Barbounis
authors.forename: H
authors.initials: H
authors.lastname: Hajichristou
authors.forename: S
authors.initials: S
authors.lastname: Tsousis
authors.forename: A
authors.initials: A
authors.lastname: Efremidis
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005260:Female; D005485:Flutamide / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D005485:Flutamide